THE SCIENCE OF SPRAVATO
The safe side of transformative mental health support.
All your ketamine questions
Ask the Experts
How does ketamine work?
When suffering chronic depression, the neurons in your brain are inflamed. That’s why the depressed version of you often feels sluggish, heavy, numb, and stuck.
Ketamine works by triggering neurogenesis, or regrowth of neurons, repairing the damage depression causes. On ketamine, your brain regenerates neurons, restores connections between neurons, and strengthens those connections.
The result? Your mind can see the world in a whole new light — and find relief, joy, and life again.
FDA-approved Spravato®: A safer standard.
Ketamine is a well-researched, regulated, and 100% legal medication when properly administered. At Marpa Minds, we go one step further, reaching for the only version of ketamine that’s actually approved by the FDA for depression: Esketamine, known as Spravato®, a nasal spray that’s patented, highly studied, and covered by insurance.
While ketamine clinics typically offer ketamine in IV form, Spravato®’s inhaled solution is far gentler and better-tolerated by most people. Fewer negative experiences means more positive ones!
Immediate relief
Compared to traditional antidepressants
Easy to administer
Nasal spray is more user-friendly than IV infusions
Fewer side effects
Side effects rarely last past 2 hour treatment window
80%
Of Marpa patients report a noticeable reduction in depressive symptoms within 24 hours of their first Spravato treatment.
6-10
# sessions are recommended for most patients to experience a significant decline in depressive symptoms.
25%
Of patients might experience transient side effects like dizziness or disassociation, which generally abate before leaving the treatment facility.
Are you eligible for Spravato?
Spravato is developed to treat for TRD, or treatment-resistant depression. Learn if it’s right for you.
You’ve been diagnosed with depression
You have tried at least 2 forms of medication
The medication has not successfully alleviated your depressive symptoms
With Marpa, a significant majority of clients experience an improvement in mood shortly after administration. — safely.
Read the Ketamine Research
A growing body of clinical research shows that ketamine can successfully treat mental health symptoms. We’ve gathered it here so you can read it for yourself!
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)
What it’s about This study found that the combination therapy of Spravato nasal spray and an oral antidepressant in TRD was well-tolerated, and no new safety concerns were identified over the long-term treatment period.
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Anxiety in Patients With Treatment-Resistant MDD: A Retrospective Chart Review
What it’s about This chart review evaluated the efficacy and safety of intranasal esketamine (Spravato) in patients with treatment-resistant depression. The study found that intranasal esketamine was effective in rapidly reducing symptoms of depression and anxiety, and was well-tolerated.
Spravato (Esketamine Nasal Spray) for Treatment-Resistant Depression: A Review of Clinical Effectiveness and Cost-Effectiveness
What it’s about This review found that Spravato was effective in reducing depressive symptoms, but the cost-effectiveness was uncertain due to limited data.
Effects of repeated ketamine infusions on cognition: Systematic review and meta-analysis
What it’s about The study found that repeated ketamine infusions did not have a significant negative impact on cognitive function in patients with treatment-resistant depression.
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
What it’s about This study found that intranasal esketamine (Spravato) was effective in rapidly reducing symptoms of depression and suicidality in patients at imminent risk for suicide. The treatment was well-tolerated, and no new safety concerns were identified.
Esketamine Nasal Spray for the Management of Treatment-Resistant Depression: A Review of Current Evidence
What it’s about This review article summarizes the current evidence on the use of esketamine nasal spray for treatment-resistant depression. The authors conclude that esketamine appears to be an effective and well-tolerated treatment option for this population.
Esketamine Nasal Spray for Major Depressive Disorder: A Review of Safety and Efficacy
What it’s about This review article discusses the safety and efficacy of esketamine nasal spray for major depressive disorder. The authors conclude that the treatment is effective, with a rapid onset of action, and that the safety profile is generally favorable.
Esketamine Nasal Spray for the Treatment of Major Depressive Disorder: A Review of Clinical and Economic Evidence
What it’s about This review article discusses the clinical and economic evidence on the use of esketamine nasal spray for major depressive disorder. The authors conclude that the treatment is effective and provides a cost-effective option for patients who have not responded to other treatments.
Esketamine Nasal Spray for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients with Major Depressive Disorder and Bipolar Depression
What it’s about This study found that esketamine nasal spray was effective in rapidly reducing symptoms of depression and suicidality in patients with major depressive disorder and bipolar depression. The treatment was well-tolerated, and no new safety concerns were identified.
